Times (CET)

Opening Remarks for the event brought to you by Cillian King, Managing Director from EQT

Moderator: Joachim Rothe, EQT

Panellists:

Jeevan Virk, Novartis

Germo Gericke, Ariceum Therapeutics

Sven Van den Berghe, PanTera

Ken Herrmann, Essen University

This panel discussion delves into the dynamic landscape of radiopharmaceuticals, focusing on key market trends and recent strategic deals shaping the industry. Experts will explore the latest clinical milestones, including advancements in radioligand technologies, and examine the evolving selection of radioisotopes critical to treatment efficacy & safety. The session will also address supply chain challenges, regulatory considerations, and innovative solutions driving growth in this rapidly advancing sector

Stepping into the boardroom is about more than just presenting information—it’s about shaping perspectives, driving decisions, and leaving a lasting impact.

This dynamic and interactive Masterclass is designed to equip you with the tools to confidently navigate the boardroom, whether you’re leading the conversation or collaborating with board members. Discover how to:

- Craft compelling materials that speak to the board’s priorities.

- Deliver impactful presentations that command attention and respect.

- Engage effectively to build credibility and trust.

Gain actionable insights and strategies that elevate your influence, helping you to make a meaningful impression where it matters most.

Join us for an experience that promises not just knowledge but transformation. The boardroom is calling—are you ready to lead?

Keynote session delivered by Lars Lannfelt, BioArctic

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are still under intense investigation, the established alterations of the biochemical amyloid cycle remain the core biological hallmark of AD and is a promising target for the development of disease-modifying therapies. Protofibrils and oligomers of amyloid β-protein (Aβ) are intermediates in the Aβ aggregation process, and hypothesised as a major culprit in the pathogenesis of AD. Thus, they represent promising targets for therapy. Lecanemab was designed to target soluble, aggregated Aβ, based on the Arctic mutation (Aβ E22G), which causes AD due to an enhanced propensity to form protofibrils. Several monoclonal antibodies targeting Aβ have failed in clincal trials due to lack of efficacy and/or adverse events. We investigated the binding profile of several antibodies in phase 3 clinical development to different forms of Aβ to better understand mode of action. Differences in binding to Aβ may mediate clinical efficacy and safety readouts observed for the antibodies. Lecanemab is now approved for treatment of early AD in large parts of the world.